TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

258 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

144 studies on the map

BOTOX® vs. XEOMIN® for Chronic Migraine — Naval Medical Center Camp Lejeune, JacksonvilleMolecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoBone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait — UConn Health, FarmingtonMigraine in Adolescents — Washington University School of Medicine, St LouisA Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring — Pfizer, New YorkResponding With Evidence and Access for Childhood Headaches — University of Alabama at Birmingham Children's of Alabama, BirminghamAchieving Understanding of the Natural History of Sickle Cell Trait (AUNT) — University of Alabama, BirminghamA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamSupraspinal Processing of Sensory Aspects of Pain — Cincinnati Children's Hospital, CincinnatiA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeRELAXaHEAD for Headache Patients (Phase III) — NYU Langone Health, New YorkA Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Ki Health Partners LLC DBA New England Institute for Clinical Research, StamfordEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaEfficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents — National Intrepid Center of Excellence (NICOE), BethesdaMetabolic Profiling of Immune Responses in Immune-mediated Diseases — National Institutes of Health Clinical Center, BethesdaCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaBE WELL With Migraine: Brain Education and WELLness With Migraine — Cambridge Health Alliance - Center for Mindfulness and Compassion, CambridgeRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US — MedStar Health: Neurology at McLean, McLeanEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — The Belinga Clinic, Fort SmithStudy to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks — Neurology and Pain Specialty Center /ID# 278508, Aliso ViejoRegistry for Systemic Eczema Treatments — Johns Hopkins University, BaltimoreStress Management and Mindfulness Intervention for Patients With Sickle Cell Disease — University of Pennsylvania, PhiladelphiaSMYLS Multi-site Trial — Medical University of South Carolina, CharlestonSickle Cell Improvement: Enhancing Care in the Emergency Department — Children's Wisconsin, MilwaukeeIntegrative Medicine in Pain Management in Sickle Cell Disease, 2.0 — Indiana University School of Medicine, IndianapolisA Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up — National Institutes of Health Clinical Center, BethesdaVerifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease — Cincinnati Children's Hospital Medical Center, CincinnatiEmgality for Migraine in Breastmilk — University of California, San Francisco, San FranciscoSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceComparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Children's of Alabama (MRD-HCT), BirminghamAdvancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease — Children's National Hospital, Washington D.C.The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamFunctional Ovarian Reserve in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamMindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease — University of Illinois Chicago, ChicagoExternal Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy — https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true, DarienA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyAcceptance and Commitment Therapy to Improve Disability in Chronic Migraine — Brigham and Women's / Faulkner Hospital, BostonA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamCocoa Extract for Migraine Trial — Brigham and Women's Hospital, BostonA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Rehabilitation and Neurological Services /ID# 270782, HuntsvilleDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreBlood Sampling for Research Related to Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaInvestigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli — University of Minnesota, MinneapolisPredictors of Pain in Sickle Cell Disease — Duke University Medical Center, DurhamAimovig Pregnancy Exposure Registry — IQVIA Virtual Site, DurhamA Real-World Registry of Chronic Wounds and Ulcers — US Wound Registry, The WoodlandsArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaNatural History and Genetics of Food Allergy and Related Conditions — National Institutes of Health Clinical Center, BethesdaA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixATHNdataset Registry — American Thrombosis and Hemostasis Network, HickoryA Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Xenoscience Inc, PhoenixEndometriosis and Migraine — Washington University School of Medicine, St LouisVirtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises — University of Maryland Medical Systems, BaltimoreStudy to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population — Syneos Health (remote site), MorrisvilleTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease — Children's Hospital of Atlanta: Eagelston, AtlantaGenotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaA Socio-ecological Approach for Improving Self-management in Adolescents With SCD — Nemours Children's Health, WilmingtonA Long-term Follow-up Study in Patients Who Received BEAM-101 — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Central Research Associates, LLC (CRA) dba Flourish Research, BirminghamA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoSickleFit Exercise and Nutrition Study — Duke University, DurhamFlourish: Exploring the Early Infant Gut Microbiome — Seeding Labs INC, AustinPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnA Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine — Flourish - Birmingham, BirminghamA Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine — Children's Mercy, Kansas CityStudy of EVO756 in Adults With Migraine — CA Medical Clinic for Headache, Los AngelesMetabolic and Hemodynamic Reserve in Pediatric SCA — Washington University in St. Louis, St LouisStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) — Rehabilitation & Neurological Services /ID# 229969, HuntsvilleSchool Readiness Intervention for Preschool Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaA Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease — University of Florida, GainesvilleMMA Embolization for Refractory Chronic Migraine — Barrow Neurological Institute at St. Joseph's Hospital, PhoenixSickle Cell, Pain and Mediterranean Diet — University of Illinois Chicago, ChicagoTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesIntegrative Training Program for Pediatric Sickle Cell Pain — Connecticut Children's Medical Center, HartfordEffectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines — Advocate Christ Medical Center Emergency Department, Oak LawnSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomMULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease — UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, ClevelandChiropractic Care for Episodic Migraine — Osher Center for Integrative Health, Mass General Brigham, BostonCorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry — CorEvitas, LLC, WalthamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockMechanistic Studies of Psilocybin in Headache Disorders — VA Connecticut Healthcare System, West HavenObservational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant — Evidera, a PPD business unit, WilmingtonCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanTopical Treatment for Atopic Dermatitis — Wake Forest University Health Sciences, Winston-SalemCooperative Assessment of Late Effects for SCD Curative Therapies — Children's National Medical Center, Washington D.C.Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy — Iqvia /Id# 266904, DurhamPromoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease — Boston Children's Hospital, BostonObservational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies — National Institutes of Health Clinical Center, BethesdaEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisRecruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease — University of Alabama, Birmingham (UAB), BirminghamStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness — Lurie Children's Hospital, ChicagoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoExercise in Child Health — University of California, Irvine, IrvineFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityA Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache — Maimonides Medical Center, BrooklynMichigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project — University of Michigan, Ann ArborPeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamAssessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA — Brown University, ProvidenceA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoStudy to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain — University of South Alabama Medical Center, MobileA Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine — Hope Clinical Research, Canoga ParkA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyStimulation of External Carotid Artery Circulation — University of Texas Medical Branch, GalvestonA Feasiblity Study of Green Activity Program for People Living With Memory Challenges — Indiana University Bloomington, BloomingtonFLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases — xCures, Los AltosStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Central Research Associates /ID# 260161, BirminghamA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. — Pfizer, New YorkA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgLight Exposure, Migraine Outcomes, and Sleep Quality — ASU DeSmart Lab, TempeReal-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine — University of Miami, Miller School of Medicine, MiamiBilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine — Johns Hopkins Medicine, BaltimoreEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications — Mayo Clinic in Arizona, Phoenix

Showing the 150 nearest — narrow your filters for fewer, closer studies.